Regeneron (REGN) Q2 FY 2018 Upside Potential is 'Substantial' - Piper
Tweet Send to a Friend
Piper Jaffray maintains Overweight on Regeneron Pharma (NASDAQ: REGN) price target of $450.00.Analyst Chris Raymond says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


